USRE41884E1 - Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions - Google Patents
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions Download PDFInfo
- Publication number
- USRE41884E1 USRE41884E1 US12/027,100 US2710008A USRE41884E US RE41884 E1 USRE41884 E1 US RE41884E1 US 2710008 A US2710008 A US 2710008A US RE41884 E USRE41884 E US RE41884E
- Authority
- US
- United States
- Prior art keywords
- agents
- drug
- particle size
- mammal
- nanoparticulate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 **OCCC1(CC)CO2(CC*2*)O1.C.C.C.C Chemical compound **OCCC1(CC)CO2(CC*2*)O1.C.C.C.C 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
- Y10T428/2985—Solid-walled microcapsule from synthetic polymer
Definitions
- the present invention is directed to nanoparticulate, liposome, emulsion and polymeric colloidal drug formulations for intravenous administration, the delivery of which to a mammal, reduces/eliminates the adverse physiological effects. More particularly, the invention relates to a method of intravenous nanoparticulate, liposome, emulsion and polymeric colloidal drug formulations to a mammal, wherein the rate of infusion and concentration of the drug is controlled.
- Nanoparticles are well know in the prior art, having been described, for example, in U.S. Pat. No. 5,145,684. These particles consist of a crystalline drug substance having a surface modifier adsorbed on the surface of the particles such that the average particle size is less than about 400 mm. Low solubility of solid drugs prompted the pharmaceutical industry to create nanoparticles of such drugs which then can be administered systematically to provide bioavailability. Drug substances disclosed which can be made into nanoparticles include a variety of known classes of drugs.
- the drug substance is comminuted in the presence of a surface active agent or, alternatively, the surface active agent is allowed to be adsorbed to the nanoparticulate drug substance after the process of comminution.
- the surface active agent prevents flocculation or congregation of the nanoparticles.
- the present invention will be described particularly in reference to nanoparticulate crystalline drug formulations, however, the invention encompasses the use of other carriers for active drugs that do not form a solution but rather a suspension or dispersion having nanoparticulates in the range of less than 1000 nm.
- a nanoparticulate drug composition at an infusion a solids dose rate not exceeding 10 mg/min
- a nanoparticulate drug composition comprising particles consisting essentially of from about 0.1 to about 99.9% by weight of a crystalline organic drug substance having a solubility in water of less than 10 mg/ml, said drug substance having a surface modifier adsorbed on the surface thereof in an amount of 0.1-99.9% by weight and sufficient to maintain an effective average particle size of from about 50 to about 1000 nm, and a pharmaceutically acceptable carrier therefor.
- the present invention provides a method of administering a nanoparticulate composition to a mammal such as a dog or other sensitive species without eliciting adverse hemodynamic effects comprising:
- intravenously administering to said dog an antihistamine including H1, H2 and H3 receptor antagonists in the amount of form about 5 to about 10 mg/kg of body weight, such as diphenhydramine, cimetidine or thioperamide or a combination thereof followed by intravenously administering to said dog an effective amount of a nanoparticulate drug composition comprising particles consisting essentially of from about 0.1 to about 99.9% by weight of a crystalline drug substance having a solubility in water of less than 10 mg/ml, said drug substance having a surface modifier adsorbed on the surface thereof in an amount of 0.1-99.0% by weight and sufficient to maintain an effective average particle size of less than 1000 nm, and preferably less than about 400 nm, and a pharmaceutically acceptable carrier thereof.
- the present invention provides a method of administering a nanoparticulate composition to a mammal, such as a dog or other sensitive species without eliciting adverse hemodynamic effects comprising: intravenously administering to said mammal a desensitizing amount of a nanoparticulate drug composition at an infusion a solids dose rate not exceeding 10 mg/min, followed by intravenous administration of an effective amount of said nanoparticulate composition comprising particles consisting essentially of from about 0.1 to about 99.9% by weight of a crystalline organic drug substance having a solubility in water of less than 10 mg/ml, said drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of from 50 to 1000 nm, and a pharamceutically acceptable carrier therefor.
- the bioactive drug is entrapped in the liposome or colloidal particles in an amount of from about 0.1 to about 99.9 to about 99.1 to about 0.1% by weight liposome or colloidal particles, such particles having a particle size of less than 1000 mm, and then administered to the patient to be treated.
- the term “desensitizing amount” means a dose low enough so as not to elicit a response but still acutely precondition the mammal so that a subsequent injection of a full dose will now be without effect.
- mammal preferably means a dog and other sensitive species including human species.
- Nanoparticulate formulations cause a significant transient decrease in arterial blood pressure immediately following intravenous injection in anesthetized dogs.
- Extensive studies were conducted to evaluate the acute hemodynamic effects of intravenously administered nanoparticles. To eliminate effects which may be caused by an active drug, inert polystyrene nanoparticles were used in the studies. Parameters were monitored throughout the studies including mean arterial pressure, heart rate, mean pulmonary arterial pressure, left ventricular systolic pressure, temperature, blood chemistry and hematology.
- Mongrel dogs of either sex weighing between 13 and 16 kg were used in these studies. Dogs were acquired form Butler Farms (Clyde, N.Y.) and allowed at least a two week acclimation period following shipment and prior to conducting these studies.
- Dogs were anesthetized with sodium pentobarbital (30 mg/kg, i.v.). Following surgical preparation, the dogs were placed on an infusion of sodium pentobarbital (4 mg/kg/hr) to maintain an adequate, constant level of anesthesia throughout the experimental protocol. All anesthetic injections were administered via a 20 gauge percutaneous venicatheter placed in the right cephalic vein.
- the right carotid artery, right femoral artery, and the right and left femoral veins were surgically isolated via percutaneous incisions and blunt dissection.
- a high fidelity, solid state, dual sensor pressure transducer catheter (Model SPC 784A, Millar Instruments, Houston, Tex.) was advanced retrograde from the carotid artery and placed into the left ventricular chamber of the heart The distal pressure sensor, positioned in the left ventricle, was used to measure intraventricular pressure and the proximal sensor, positioned at the root of the aorta, measured intra-aortic pressure.
- the pulsatile left ventricular pressure (LVP) signal was electronically differentiated (dP/dt) to acquire an estimate of cardiac contractility (LV dP/dt).
- Heart rate (HR) was also derived from the pulsatile LVP signal.
- Mean arterial blood pressure (MAP) was derived form the pulsatile signal of intraaortic pressure.
- Another fluid-filled catheter was placed in the right femoral artery for acquisition of arterial blood samples for blood gas measurements. Arterial blood pH, PCO 2 and p O 2 were measured on freshly drawn samples using an automated blood gas analyzer (Model ABL30, Radiometer Corp., Westlake, Ohio). Platinum pin electrodes were inserted subcutaneously to monitor lead II electrocardiogram. All particles were injected in the left cephalic vein via a 20 gauge percutaneous venicatheter.
- Polystyrene particles having a diameter of 200 nm were obtained form Polysciences, Inc.
- a 10% solution of F108 was made by weighing out 1 g of F108 in a 50 ml plastic beaker and then adding 8 ml of water (Sterile water for injection—SWFI) to the surfactant.
- SWFI benzyl alcohol
- the beaker was placed in the refrigerator until the surfactant had gone into solution.
- SWIF was added to bring the final volume to 10 mls which was then filtered with a 0.1 ⁇ m syringe filter before use.
- the suspension of 5% WIN 8883+5% F108 was prepared analogously to the 5% Polystyrene+5% F108 suspension shown in #2.
- Supernatant of WIN 8883 was prepared by centrifugation of a sample of WIN 8883 at 20,000 g for 1 hour, followed by recentrifugation of the decanted supernatant 5% WIN 8883. No WIN 8883 was found in the decanted solution.
- the supernatant was prepared analogously to that shown in #4. No polystyrene was found in the supernatant.
- the preparations of #1, #2, #3, #4 and #5 were administered to groups of dogs subcutaneously and intravenously at various dose levels described below. Baseline hemodynamics were recorded for a 10 minute period just prior to administration of the preparations. Following administration of the preparation each dog was monitored 60 minutes.
- “uncoated” polystyrene nanoparticles administered at a dose of 0.1 ml/kg of body weight and a rate of 1 ml/min does not induce hemodynamic effect.
- “uncoated” nano-particle drugs cannot be administered safely, since they coagulate/flocculate causing deleterious side effects. Accordingly, active drugs must be surfactant coated to circumvent coagulation/flocculation of the nanoparticles.
- Hemodynamic effect is associated with the surfactant-particle combination. While the inventors would not want to be limited to a theory of mechanism in the practice of their invention, it appears that the particles act as carrier for the surfactant, delivering it to its site of action in the blood stream. Theoretically, the uncoated particle also accesses the site of action but cannot initiate the response in the absence of the surfactant. Conversely, in the absence of particles, the surfactant also cannot access the site of action and does not initiate the response.
- the particles comprise a therapeutic or diagnostic agent, (therapeutic agents are sometimes referred to as drugs or pharmaceuticals.
- the diagnostic agent referred to is typically a contrast agent such as an x-ray contrast agent but can also be other diagnostic materials.)
- the therapeutic or diagnostic agent exists as a discrete, crystalline phase.
- the crystalline phase differs from a non-crystalline or amorphous phase which results from precipitation techniques, such as described in EPO 275,796.
- the invention can be practiced with a wide variety of therapeutic or diagnostic agents.
- the therapeutic or diagnostic agent preferably is present in an essentially pure form.
- the therapeutic or diagnostic agent must be poorly soluble and dispersible in at least one liquid medium.
- “poorly soluble” it is meant that the therapeutic or diagnostic agent has a solubility in the liquid dispersion medium of less than about 10 mg/ml, and preferably of less than about 1 mg/ml.
- a preferred liquid dispersion medium is water.
- the invention can be practiced with other liquid media in which a therapeutic or diagnostic agent is poorly soluble and dispersible including, for example, aqueous salt solutions, safflower oil and solvents such as ethanol, t-butanol, hexane and glycol.
- the pH of the aqueous dispersion media can be adjusted by techniques known in the art.
- Suitable therapeutic or diagnostic agents can be selected from a variety of known classes of therapeutic or diagnostic agents including, for example, anti-inflammatory agents, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), beta-adrenoceptor blocking agents, cardiac inotropic agents, contrast media, corticosteroids, diagnostic agents, diagnostic imaging agents, dopaminergics (antiparkinsonian agents), haemostatics, immuniological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio- pharmaceuticals, sex hormones (including steroids), anti-allergic agents,
- Preferred diagnostic agents include the x-ray imaging agent WIN-8883 (ethyl 3,5- diacetamido-2,4,6triiodobenzoate) also known as the ethyl ester of diatrazoic acid (EEDA), WIN 67722, i.e., (6-ethoxy-6-oxohexyl-3,5-bis(acetamido)- 2,4,6-triiodobenzoate; ethyl-2-(3,5-bis (acetamido)-2,4,6-triiodobenzoyloxy)butyrate (WIN 16318); ethyl diatrizoxyacetate (WIN 12901); ethyl 2-(3,5bis(acetamido)-2,4,6-triiodobenzoyloxypropionate (WIN 16923); N-ethyl 2-(3,5-bis(acetamido)-2,4,6triiodobenzoyloxy ace
- Preferred contrast agents include those which are expected to disintegrate relatively rapidly under physiological conditions, thus minimizing any particle associated inflammatory response.
- Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products and surfactants. Preferred surface modifiers include nonionic and ionic surfactants.
- surface modifiers include gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, e.g., macrogol ethers such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available TweensTM, polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethyl cellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxy propylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, poly(ethylene
- Particularly preferred surface modifiers include polyvinylpyrrolidone, tyloxapol, poloxamers such as PluronicsTM F68 and F108, which are block copolymers of ethylene oxide and propylene oxide, and polyxamines such as TetronicsTM 908 (also known as PoloxamineTM 908), which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, available from BASF, dextran, lecithin, dialkylesters of sodium sulfosuccinic acid, such as Aerosol OTsTM, which is a dioctyl ester of sodium sulfosuccinic acid, available from American Cyanimid, DuponolsTM P, which is a sodium lauryl sulfate, available from DuPont, TritonsTM X-200, which is an alkyl aryl polyether sulfonate, available from Rohn and Haas, T
- tyloxapol a nonionic liquid polymer of the alkyl aryl polyether alcohol type; also known as superinone or triton. This surface modifier is commercially available and/or can be prepared by techniques known in the art.
- Another preferred surface modifier is p-isononylphenoxypoly(glycidol) also known as Olin-10GTM or Surfactant 10-G, is commercially available as 10GTM from Olin Chemicals, Stamford, Conn.
- Preferred surface modifiers can be selected from known non-ionic surfactants, including the poloxamines such as TetronicTM908 (also known as PoloxanmineTM908), which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, available from BASF, or TetronicTM 1508 (T-1508), or a polymer of the alkyl aryl polyether alcohol type, such as tyloxapol.
- TetronicTM908 also known as PoloxanmineTM908
- T-1508 TetronicTM 1508
- a polymer of the alkyl aryl polyether alcohol type such as tyloxapol.
- the surface modifiers are commercially available and/or can be prepared by techniques known in the art. Two-or more surface modifiers can be used in combination.
- auxiliary surface modifiers are those which impart resistance to particle aggregation during sterilization and include dioctylsulfosuccinate (DOSS), polyethylene glycol, glycerol, sodium dodecyl sulfate, dodecyl trimethyl ammonium bromide and a charged phospholipid such as dimyristoyl phophatidyl glycerol.
- DOSS dioctylsulfosuccinate
- polyethylene glycol glycerol
- sodium dodecyl sulfate sodium dodecyl sulfate
- dodecyl trimethyl ammonium bromide and a charged phospholipid such as dimyristoyl phophatidyl glycerol.
- the surface modifiers are commercially available and/or can be prepared by techniques known in the art. Two or more surface modifiers can be used in combination.
- One preferred surface modifier is a block copolymer linked to at least one anionic group.
- the polymers contain at least one, and preferably two, three, four or more anionic groups per molecule.
- Preferred anionic groups include sulfate, sulfonate, phosphonate, phosphate and carboxylate groups.
- the anionic groups are covalently attached to the nonionic block copolymer.
- the nonionic sulfated polymeric surfactant has a molecular weight of 1,000-50,000, preferably 2,000-40,000 and more preferably 3,000-30,000.
- the polymer comprises at least about 50%, and more preferably, at least about 60% by weight of hydrophilic units, e.g., alkylene oxide units. The reason for this is that the presence of a major weight proportion of hydrophilic units confers aqueous solubility to the polymer.
- a preferred class of block copolymers useful as surface modifiers herein includes sulfated block copolymers of ethylene oxide and propylene oxide. These block copolymers in an unsulfated form are commercially available as PluronicsTM. Specific examples of the unsulfated block copolymers include F68, F108 and F127.
- block copolymers useful herein include tetrafunctional block copolymers derived from sequential addition of ethylene oxide and propylene oxide to ethylene diamine. These polymers, in an unsulfated form, are commercially available as TetronicsTM.
- Another preferred class of surface modifiers contain at least one polyethylene oxide (PEO) block as the hydrophilic portion of the molecule and at least one polybutylene oxide (PBO) block as the hydrophobic portion.
- PEO polyethylene oxide
- PBO polybutylene oxide
- Particularly preferred surface modifiers of this class are diblock, triblock, and higher block copolymers of ethylene oxide and butylene oxide, such as are represented, for example, by the following structural formula: POE PBO PEO PBO PEO ; and PEO PBO PEO PBO .
- the block copolymers useful herein are known compounds and/or can be readily prepared by techniques well known in the art.
- Highly preferred surface modifiers include triblock copolymers of the PEO PBO PEO having molecular weights of 3800 and 5000 which are commercially available from Dow Chemical, Midland, Michigan, and are referred to as B20-3800 and B20-5000. These surface modifiers contain about 80% by weight PEO.
- the surface modifier is a triblock polymer having the structure: Q is an anionic group
- the described particles can be prepared in a method comprising the steps of dispersing a therapeutic or diagnostic agent in a liquid dispersion medium and applying mechanical means in the presence of grinding media to reduce the particle size of the therapeutic or diagnostic agent to an effective average particle size of less than about 1000 nm, and preferably of less than about 400 nm.
- the particles can be reduced in size in the presence of a surface modifier.
- the particles can be contacted with a surface modifier after attrition.
- the therapeutic or diagnostic agent selected is obtained commercially and/or prepared by techniques known in the art in a conventional coarse form. It is preferred, but not essential, that the particle size of the coarse therapeutic or diagnostic agent selected be less than about 10 mm as determined by sieve analysis. If the coarse particle size of the therapeutic or diagnostic agent is greater than about 100 mm, then it is preferred that the particles of the therapeutic or diagnostic agent be reduced in size to less than 100 mm using a conventional milling method such as airjet or fragmentation milling.
- the coarse therapeutic or diagnostic agent selected can then be added to a liquid medium in which it is essentially insoluble to form a premix.
- concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0.1-60%, and preferably is from 5-30% (w/w). It is preferred, but not essential, that the surface modifier be present in the premix.
- concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably is 1-75%, more preferably 20-60%, by weight based on the total combined weight of the therapeutic or diagnostic agent and surface modifier.
- the apparent viscosity of the premix suspension is preferably less than about 1000 centipoise.
- the premix can be used directly by subjecting it to mechanical means to reduce the average particle size in the dispersion to less than 1000 nm. It is preferred that the premix be used directly when a ball mill is used for attrition.
- the therapeutic or diagnostic agent and, optionally, the surface modifier can be dispersed in the liquid medium using suitable agitation, e.g., a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates-visible to the naked eye. It is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.
- the therapeutic or diagnostic agnet and, optionally, the surface modifier can be dispersed in the iquid medium using suitable agitiation, e.g., a roller mill or a Cowles type mixer, until a homogeneous dispersion is observed in which there are no large agglomerates visible to the naked eye. It is preferred that the premix be subjected to such a premilling dispersion step when a recirculating media mill is used for attrition.
- the mechanical means applied to reduce the particle size of the therapeutic or diagnostic agent conveniently can take .
- Suitable dispersion mills include a ball mill, an attritor mill, a vibratory mill, and media mills such as a sand mill and a bead mill.
- a media mill is preferred due to the relatively shorter milling time required to provide the intended result, desired reduction in particle size.
- the apparent viscosity of the premix preferably is from about 100 to about 1000 centipoise.
- the apparent viscosity of the premix preferably is from about 1 up to about 100 centipoise. Such ranges tend to afford an optimal balance between efficient particle fragmentation and media erosion.
- the attrition time can vary widely and depends primarily upon the particular mechanical means and processing conditions selected. For ball mills, processing times of up to five days or longer may be required. On the other hand, processing times of less than 1 day (residence times of one minute up to several hours) have provided the desired results using a high shear media mill.
- the particles must be reduced in size at a temperature which does not significantly degrade the therapeutic or diagnostic agent. Processing temperatures of less than about 30°-40° C. are ordinarily preferred. If desired, the processing equipment can be cooled with conventional cooling equipment. The method is conveniently carried out under conditions of ambient temperature and at processing pressures which are safe and effective for the milling process. For example, ambient processing pressures are typical of ball mills, attritor mills and vibratory mills. Control of the temperature, e.g., by jacketing or immersion of the milling chamber in ice water are contemplated. Processing pressures from about 1 psi (0.07 kg/cm2) up to about 50 psi (3.5 kg/cm2) are contemplated. Processing pressures from about 10 psi (0.7 kg/cm2) to about 20 psi 1.4 kg/cm2)
- the surface modifier if it was not present in the premix, must be added to the dispersion after attrition in an amount as described for the premix above. Thereafter, the dispersion can be mixed, e.g., by shaking vigorously.
- the dispersion can be subjected to a sonication step, e.g., using an ultrasonic power supply.
- the dispersion can be subjected to ultrasonic energy having a frequency of 20-80 kHz for a time of about 1 to 120 seconds.
- the grinding media is separated from the milled particulate product (in either a dry or liquid dispersion form) using conventional separation techniques, such as by filtration, sieving through a mesh screen, and the like.
- the grinding media for the particle size reduction step can be selected from rigid media preferably spherical or particulate in form having an average size less than about 3 mm and, more preferably, less than about 1 mm. Such media desirably can provide the particles with shorter processing times and impart less wear to the milling equipment.
- the selection of material for the grinding media is not believed to be critical.
- zirconium oxide, such as 95% ZrO2 stabilized with magnesia, zirconium silicate, and glass grinding media provide particles having levels of contamination which are believed to be acceptable for the preparation of pharmaceutical compositions.
- other media such as stainless steel, titania, alumina, and 95% ZrO2 stabilized with yttrium, are expected to be useful.
- Preferred media have a density greater than about 3 g/cm3.
- the grinding media can comprise particles, preferably substantially spherical in shape, e.g., beads, consisting essentially of polymeric resin.
- the grinding media can comprise particles comprising a core having a coating of the polymeric resin adhered thereon.
- polymeric resins suitable for use herein are chemically and physically inert, substantially free of metals, solvent and monomers, and of sufficient hardness and friability to enable them to avoid being chipped or crushed during grinding.
- Suitable polymeric resins include crosslinked polystyrenes, such as polystyrene crosslinked with divinylbenzene, styrene copolymers, polycarbonates, polyacetals, such as DelrinTM, vinyl chloride polymers and copolymers, polyurethanes, polyamides, poly (tetrafluoroethylenes), e.g., TeflonTM, and other fluoropolymers, high density polyethylenes, polypropylenes, cellulose ethers and esters such as cellulose acetate, polyhydroxymethacrylate, polyhydroxyethyl acrylate, silicone containing polymers such as polysiloxanes and the like.
- the polymer can be biodegradable.
- biodegradable polymers include poly(lactides), poly (glycolide) copolymers of lactides and glycolide, polyanhydrides, poly(hydroxyethyl methacylate), poly (imino carbonates), poly(N-acylhydroxyproline)esters, poly (N-palmitoyl hydroxyproline) esters, ethylene-vinyl acetate copolymers, poly(orthoesters), poly(caprolactones), and poly(phosphazenes).
- contamination from the media itself advantageously can metabolize in vivo into biologically acceptable products which can be eliminated from the body.
- the polymeric resin can have a density from 0.8 to 3.0 g/cm3. Higher density resins are preferred inasmuch as it is believed that these provide more efficient particle size reduction.
- the media can range in size from about 0.1 to 3 mm.
- the particles preferably are from 0.2 to 2 mm, more preferably, 0.25 to 1 mm in size.
- a therapeutic or diagnostic agent is prepared in the form of submicron particles by grinding the agent in the presence of a grinding media having a mean particle size of less than about 75 microns.
- the core material of the grinding media preferably can be selected from materials known to be useful as grinding media when fabricated as spheres or particles.
- Suitable core materials include zirconium oxides (such as 95% zirconium oxide stabilized with magnesia or yttrium), zirconium silicate, glass, stainless steel, titania, alumina, ferrite and the like.
- Preferred core materials have a density greater than about 2.5 g/cm 3 . The selection of high density core materials is believed to facilitate efficient particle size reduction.
- Useful thicknesses of the polymer coating on the core are believed to range from about 1 to about 500 microns, although other thicknesses outside this range may be useful in some applications.
- the thickness of the polymer coating preferably is less than the diameter of the core.
- the cores can be coated with the polymeric resin by techniques known in the art. Suitable techniques include spray coating, fluidized bed coating, and melt coating. Adhesion promoting or tie layers can optionally be provided to improve the adhesion between the core material and the resin coating. The adhesion of the polymer coating to the core material can be enhanced by treating the core material to adhesion promoting procedures, such as roughening of the core surface, corona discharge treatment, and the like.
- the particles are made continuously rather than in a batch mode.
- the continuous method comprises the steps of continuously introducing the therapeutic or diagnostic agent and rigid grinding media into a milling chamber, contacting the agent with the grinding media while in the chamber to reduce the particle size of the agent, continuously removing the agent and the grinding media from the milling chamber, and thereafter separating the agent from the grinding media.
- the therapeutic or diagnostic agent and the grinding media are continuously removed from the milling chamber. Thereafter, the grinding media is separated from the milled particulate agent (in either a dry or liquid dispersion form) using conventional separation techniques, in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques such as centrifugation may also be employed.
- the agent and grinding media are recirculated through the milling chamber.
- suitable means to effect such recirculation include conventional pumps such as peristaltic pumps, diaphragm pumps, piston pumps, centrifugal pumps and other positive displacement pumps which do not use sufficiently close tolerances to damage the grinding media.
- Peristaltic pumps are generally preferred.
- Another variation of the continuous process includes the use of mixed media sizes.
- larger media may be employed in a conventional manner where such media is restricted to the milling chamber.
- Smaller grinding media may be continuously recirculated through the system and permitted to pass through the agitated bed of larger grinding media.
- the smaller media is preferably between about 1 and 300 mm in mean particle size and the larger grinding media is between about 300 and 1000 mm in mean particle size.
- Another method of forming the desired nanoparticle dispersion is by microprecipitation. This is a method of preparing stable dispersions of therapeutic and diagnostic agents in the presence of a surface modifying and colloid stability enhancing surface active agent free of trace of any toxic solvents or solubilized heavy metal inpurities by the following procedural steps:
- This microprecipitation process produces dispersion of therapeutic or diagnostic agents with Z-average particle diameter less than 400 nm (as measured by photon correlation spectroscopy) that are stable in particle size upon keeping under room temperature or refrigerated conditions. Such dispersions also demonstrate limited particle size growth upon autoclave-decontamination conditions used for standard blood-pool pharmaceutical agents.
- Step 3 can be carried out in semicontinuous, continuous batch, or continuous methods at constant flow rates of the reacting components in computercontrolled reactors or in tubular reactors where reaction pH can be kept constant using pH-stat systems. Advantages of such modifications are that they provide cheaper manufacturing procedures for large-scale production of nanoparticulate dispersion systems.
- Additional surface modifier may be added to the dispersion after precipitation. Thereafter, the dispersion can be mixed, e.g., by shaking vigorously.
- the dispersion can be subjected to a sonicationstep, e.g., using an ultrasonic power supply.
- the dispersion can be subjected to ultrasonic energy having a frequency of 20-80 kHz for a time of about 1 to 120 seconds.
- step 4 comprises removing the formed salts by diafiltration or dialysis. This is done in the case of dialysis by standard dialysis equipment and by diafiltration using standard diafiltration equipment known in the art.
- the final step is concentration to a desired concentration of the agent dispersion. This is done either by diafiltration or evaporation using standard equipment known in this art
- microprecipitation is that unlike milled dispersion, the final product is free of heavy metal contaminants arising from the milling media that must be removed due to their toxicity before product is formulated.
- a further advantage of the microprecipitation method is that unlike solvent precipitation, the final product is free of any trace of trace solvents that may be toxic and must be removed by expensive treatments prior to final product formulation.
- a crystal growth modifier is used.
- a crystal growth modifier is defined as a compound that in the co-precipitation process incorporates into the crystal structure of the microprecipitated crystals of the pharmaceutical agent, thereby hindering growth or enlargement of the microcrystalline precipitate, by the so called Ostwald ripening process.
- a crystal growth modifier (or a CGM) is a chemical that is at least 75% identical in chemical structure to the pharmaceuticl agent.
- identity is meant that the structures are identical atom for atom and their connectivity. Structural identity is charactarized as having 75% of the chemical structure, on a molecular weight basis, identical to the therapeutic or diagnostic agent. The remaining 25% of the structure may be absent or replaced by different chemical structure in the CGM.
- the crystal growth modifier is dissolved in step #1 with the therapeutic or diagnostic agent.
- particle size refers to a number average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, or disk centrifugation.
- PCS photon correlation spectroscopy
- an effective average particle size of less than about 1000 nm it is meant that at least 90% of the particles have a weight average particle size of less than about 1000 nm when measured by the above-noted techniques.
- the effective average particle size is less than about 400 nm and more preferrably less than about 300 nm.
- an effective average particle size of less than about 100 nm has been achieved. With reference to the effective average particle size, it is preferred that at least 95% and, more preferably, at least 99% of the particles have a particle size less than the effective average, e.g., 1000 nm. In particularly preferred embodiments essentially all of the particles have a size less than 1000 nm. In some embodiments, essentially all of the particles have a size less than 400 nm.
- the relative amount of therapeutic or diagnostic agent and surface modifier can vary widely and the optimal amount of the surface modifier can depend, for example, upon the particular therapeutic or diagnostic agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic lipophilic balance (HLB) of the stabilizer, the melting point of the stabilizer, its water solubility, the surface tension of water solutions of the stabilizer, etc.
- the surface modifier preferably is present in an amount of about 0.1-10 mg per square meter surface area of the therapeutic or diagnostic agent.
- the surface modifier can be present in an amount of 0.1-90%, preferably 20-60% by weight based on the total weight of the dry particle.
- a method for diagnostic imaging for use in medical procedures in accordance with this invention comprises intravenously administering to the body of a test subject in need of a diagnostic image an effective contrast producing amount of the diagnostic image contrast composition. Thereafter, at least a portion of the body containing the administered contrast agent is exposed to x-rays or a magnetic field to produce an x-ray or magnetic resonance image pattern corresponding to the presence of the contrast agent. The image pattern can then be visualized.
- Any x-ray visualization technique preferably, a high contrast technique such as computed tomography, can be applied in a conventional manner.
- the image pattern can be observed directly on an x-ray sensitive phosphor screen-silver halide photographic film combination or by use of a storage phosphor screen.
- Visualization with a magnetic resonance imaging system can be accomplished with commercially available magnetic imaging systems such as a General Electric 1.5 T Sigma imaging system [1H resonant frequency 63.9 megahertz (MHz)].
- Commercially available magnetic resonance imaging systems are typically characterized by the magnetic field strength used, with a field strength of 2.0 Tesla as the current maximum and 0.2 Tesla as the current minimum.
- each detected nucleus has a characteristic frequency.
- the resonance frequency for hydrogen is 42.57 10 MHz; for phosphorus-31 it is 17.24 MHz; and for sodium23 it is 11.26 Mhz.
- a contrast effective amount of the diagnostic agent containing composition is that amount necessary to provide tissue visualization with, for example, magnetic resonance imaging or x-ray imaging.
- Means for determining a contrast effective amount in a particular subject will depend, as is well known in the art, on the nature of the magnetically reactive material used, the mass of the subject being imaged, the sensitivity of the magnetic resonance or x-ray imaging system and the like.
- a sufficient time period is from about 20 minutes to about 90 minutes and, preferably from about 20 minutes to about 60 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
-
- Mean arterial blood pressure (MAP; mmHg)
- Heart rate (HR; min−1)
- Mean pulmonary arterial blood pressure (PAP; mmHg)
- Left ventricular systolic blood pressure (LVPsys; mmHg)
- Maximum left ventricular dP/dt (+LV dP/dt mmHg sec−1)
- Maximum left ventricular dP/dt (−LV dP/dt mmHg sec−1)
-
- Systemic arterial vascular resistance (SVR; calculated as MAP/CO; mmHg L−1 min)
- Pulmonary vascular resistance (PVR; calculated as PAP/CO; mmHg L−1 min)
- Stroke volume (SV; calculated as CO/HR.1000; cc).
- Data were down-loaded onto a PC-based statistical package CRUNCH (Crunch Software Corporation, Oakland, Calif.). An analysis of variance followed by a Dunnett's comparison was used to test the effect of dose within each group. Between group effects (WIN 8883 vs. vehicle) were analyzed using a t-test. In all cases, data are expressed as mean±s.c.
TABLE 1 |
Effect of the vehicle 5% F108 and a particulate-free supernatant on the |
hemodynamic and hematological response in dogs when infused at a rate |
of 5 ml/min and a dose of 0.1 ml/kg. Values listed as means ± S.E. |
% Change from Baseline | ||||
Treatment | N | MAP | ||
#5% F108 | 4 | −1 ± 1 | ||
#5 Supernatant | 3 | −1 ± 1 | ||
wherein: | ||||
N = no. of dogs | ||||
MAP = Mean Arterial Blood Pressure |
TABLE 2 |
Effect of uncoated and F108 (5%) coated 200 nM nm diameter |
polystyrene nanospheres, 5% suspension, infused at a rate of 1 ml/min and |
a dose of 0.1 ml/kg on the hemodynamic and a hematological response in |
dogs. Values listed as means ± S.E. |
% Change from Baseline | ||||
Treatment | N | MAP | ||
#4 Uncoated | 3 | −1 ± 1 | ||
#3 Coated | 4 | −50 ± 7 | ||
wherein: | ||||
N = no. of dogs | ||||
MAP = Mean Arterial Blood Pressure |
TABLE 3 |
Effect of rate of infusion of 200 nM nm diameter polystyrene |
nanospheres on the hemodynamic and hematological response in dogs. |
Each formulation was prepared as a 1% (w:v) suspension in a solution of |
5% F108 and administered intravenously at a dose of 0.1 ml/kg. |
Values listed as means ± S.E. |
Rate | % Change from Baseline | |
(ml/min) | N | MAP |
5 | 3 | −39 ± 15 |
1 | 4 | −26 ± 5 |
0.5 | 3 | −5 ± 1 |
wherein: | ||
N = no. of dogs | ||
MAP = Mean Arterial Blood Pressure |
TABLE 4 |
Effect of rate of infusion of 200 nM nm diameter polystyrene |
nanospheres on the hemodynamic and hematological response in dogs. |
Each formulation was prepared as a 5% (w:v) suspension in a solution of |
5% F108 and administered intravenously at a dose of 0.1 ml/kg. |
Values listed as means ± S.E. |
Rate | % Change from Baseline | |
(ml/min) | N | MAP |
1 | 4 | −50 ± 7 |
0.1 | 3 | −1 ± 1 |
wherein: | ||
N = no. of dogs | ||
MAP = Mean Arterial Blood Pressure |
TABLE 5 |
Effect of pretreatment with antihistamines on the hemodynamic and |
hematological response in dogs following ontravenous administration |
of a 1% (w:v) suspension of polystyrene nanospheres, 200 nM nm in |
diameter in a 5% solution of F108 at a dose of 0.1 ml/kg and a rate of |
5 ml/min. Values listed as means ± S.E. |
% Change from Baseline | ||||
Antihistamine | N | MAP | ||
None | 3 | −39 ± 15 | ||
Diphenhydramine 10 mg/kg | 4 | −7 ± 1 | ||
Cirnetidine 5 mg/kg | ||||
Diaphenhydramine 10 mg/kg | 3 | −4 ± 2 | ||
Cimetifine 5 mg/kg | ||||
Thioperamide 5 mg/kg | ||||
wherein: | ||||
N = no. of dogs | ||||
MAP = Mean Arterial Blood Pressure |
TABLE 6 |
Effect of particle size on the hemodynamic and hematological |
response in dogs. Each formulation was prepared as a 1% (w:v) |
suspension in a 5% solution of F108 and administered intravenously |
at a dose of 0.1 ml/kg and a rate of 5 ml/min. |
Values listed as means ± S.E. |
Diameter | % Change from Baseline | |
nMnm | N | MAP |
200 | 3 | −39 ± 15 |
100 | 4 | −26 ± 14 |
50 | 3 | −8 ± 5 |
wherein: | ||
N = no. of dogs | ||
MAP = Mean Arterial Blood Pressure |
TABLE 7 | |||
% Solids | Infusion Rate | Solids Dose Rate | Response |
(w/v) | (ml/min) | (mg/ml/min)(mg/min) | Y or N |
5 (50 mg/ml) | 1 | 50 | Y |
1 (10 mg/ml) | 10 | 100 | Y |
1 (10 mg/ml) | 5 | 50 | Y |
1 (10 mg/ml) | 1 | 10 | Y |
5 (50 mg/ml) | 0.1 | 5 | N |
10 ng/ml | 0.5 | 5 | N |
1 (10 mg/ml) | |||
-
- decanoyl-N-methylglucamide;
- n-decyl β-D-glucopyranoside;
- n-decyl β-D-maltopyranoside;
- n-dodecyl β-D-glucopyranoside;
- n-dodecyl β-D-maltoside;
- heptanoyl-N-methylglucamide;
- n-heptyl-β-D-glucopyranoside;
- n-heptyl β-D-thioglucoside; n-hexyl β-D-glucopyranoside;
- nonanoyl-N-methylglucamide;
- n-noyl β-D-glucopyranoside;
- octanoyl-N-methylglucamide;
- n-octyl-β-D-glucopyranoside;
- octyl β-D-thioglucopyranoside; and the like.
POE PBO PEO PBO PEO; and PEO PBO PEO PBO.
The block copolymers useful herein are known compounds and/or can be readily prepared by techniques well known in the art.
Q is an anionic group
-
- wherein R is H or a metal cation such as Na+, K+ and the like, x is 15-700, Y is 5-200 and z is 15-700.
Claims (35)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/027,100 USRE41884E1 (en) | 1995-09-29 | 2008-02-06 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US448895P | 1995-09-29 | 1995-09-29 | |
US08/696,754 US5834025A (en) | 1995-09-29 | 1996-08-14 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US12/027,100 USRE41884E1 (en) | 1995-09-29 | 2008-02-06 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/696,754 Reissue US5834025A (en) | 1995-09-29 | 1996-08-14 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE41884E1 true USRE41884E1 (en) | 2010-10-26 |
Family
ID=26673068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/696,754 Ceased US5834025A (en) | 1995-09-29 | 1996-08-14 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US12/027,100 Expired - Lifetime USRE41884E1 (en) | 1995-09-29 | 2008-02-06 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/696,754 Ceased US5834025A (en) | 1995-09-29 | 1996-08-14 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Country Status (6)
Country | Link |
---|---|
US (2) | US5834025A (en) |
EP (2) | EP2275094A3 (en) |
JP (1) | JP2001518059A (en) |
AU (1) | AU7117196A (en) |
CA (1) | CA2232879C (en) |
WO (1) | WO1997011686A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110124656A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
US9150517B2 (en) | 2012-11-12 | 2015-10-06 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9474728B2 (en) | 2010-06-24 | 2016-10-25 | Tonix Pharma Holdings Limited | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
US9636408B2 (en) | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10357465B2 (en) | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
US10500165B2 (en) | 2014-07-03 | 2019-12-10 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Purified therapeutic nanoparticles and preparation methods thereof |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
US11826321B2 (en) | 2017-12-11 | 2023-11-28 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69633222T2 (en) * | 1995-02-24 | 2005-09-08 | Elan Pharma International Ltd. | NANOPARTICLE DISPERSIONS CONTAINING AEROSOLS |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US6884842B2 (en) | 1997-10-14 | 2005-04-26 | Alnis Biosciences, Inc. | Molecular compounds having complementary surfaces to targets |
UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
AU764001B2 (en) | 1998-05-29 | 2003-08-07 | Skyepharma Canada Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6969529B2 (en) | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
SK288117B6 (en) | 1998-11-20 | 2013-09-03 | Skyepharma Canada Inc. | Rapidly dispersing solid dry therapeutic dosage form |
US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
AU2001288471B2 (en) | 2000-08-31 | 2006-03-02 | Rtp Pharma Inc. | Milled particles |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
KR100915741B1 (en) | 2001-06-15 | 2009-09-04 | 코너스톤 파마슈티칼스 | Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
CA2451161A1 (en) * | 2001-06-22 | 2003-01-03 | Elan Pharma International, Ltd. | Method for high through put screening using a small scale mill or microfluidics |
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
JP4464129B2 (en) * | 2001-09-19 | 2010-05-19 | エラン ファーマ インターナショナル,リミティド | Nanoparticulate insulin preparation |
PT1443912E (en) * | 2001-10-12 | 2007-11-28 | Elan Pharma Int Ltd | Compositions having a combination of immediate release and controlled release characteristics |
CA2461556A1 (en) * | 2001-10-15 | 2003-04-24 | Crititech, Inc. | Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment |
PT1471887E (en) | 2002-02-04 | 2010-07-16 | Elan Pharma Int Ltd | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US20030215502A1 (en) * | 2002-03-20 | 2003-11-20 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
ATE385777T1 (en) * | 2002-03-20 | 2008-03-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS |
WO2003082213A2 (en) * | 2002-03-28 | 2003-10-09 | Imcor Pharmaceutical Company | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
AU2003230885A1 (en) | 2002-04-12 | 2003-10-27 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
EP1503737B1 (en) * | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
WO2003103632A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
AU2003261167A1 (en) * | 2002-07-16 | 2004-02-02 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
AU2003304237A1 (en) * | 2002-09-11 | 2005-01-13 | Elan Pharma International Ltd. | Gel-stabilized nanoparticulate active agent compositions |
AU2003297151A1 (en) * | 2002-12-17 | 2004-07-22 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
EP1587499A1 (en) * | 2003-01-31 | 2005-10-26 | Elan Pharma International Limited | Nanoparticulate topiramate formulations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US7842232B2 (en) * | 2003-05-22 | 2010-11-30 | Elan Pharma International, Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
JP2007501839A (en) * | 2003-08-08 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | New metaxalone composition |
EP1686962B9 (en) * | 2003-11-05 | 2012-10-03 | Elan Pharma International Limited | Nanoparticulate compositions having a peptide as a surface stabilizer |
US9040090B2 (en) | 2003-12-19 | 2015-05-26 | The University Of North Carolina At Chapel Hill | Isolated and fixed micro and nano structures and methods thereof |
EP3242318A1 (en) | 2003-12-19 | 2017-11-08 | The University of North Carolina at Chapel Hill | Monodisperse micro-structure or nano-structure product |
WO2006055603A2 (en) * | 2004-11-16 | 2006-05-26 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
JP2008524239A (en) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | Nanoparticulate tacrolimus formulation |
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
CN101132770A (en) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | Nanoparticulate candesartan formulations |
JP2008530134A (en) | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate benzodiazepine aerosol and injectable formulations |
KR20080003322A (en) * | 2005-02-24 | 2008-01-07 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate formulations of docetaxel and analogues thereof |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
CA2601179A1 (en) * | 2005-03-16 | 2006-09-21 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
NZ561666A (en) * | 2005-03-17 | 2010-05-28 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions |
CN101180038A (en) * | 2005-03-23 | 2008-05-14 | 伊兰制药国际有限公司 | Nanoparticulate corticosteroid and antihistamine formulations |
MX2007012762A (en) * | 2005-04-12 | 2008-01-14 | Elan Pharma Int Ltd | Nanoparticulate and controlled release compositions comprising cyclosporine. |
WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
CN101198314A (en) * | 2005-04-12 | 2008-06-11 | 伊兰制药国际有限公司 | Nanoparticulate quinazoline derivative formulations |
CA2604281A1 (en) * | 2005-04-13 | 2006-10-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives |
DE112006001606T5 (en) | 2005-06-08 | 2009-07-09 | Elan Pharma International Ltd., Athlone | Nanoparticulate and controlled release composition comprising cefditoren |
CA2612384A1 (en) * | 2005-06-15 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate azelnidipine formulations |
JP2009508859A (en) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate aripiprazole formulation |
US7723345B2 (en) | 2005-12-29 | 2010-05-25 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
UA99270C2 (en) | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8974827B2 (en) | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US9724362B2 (en) | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
EP3045043B1 (en) | 2009-02-26 | 2020-04-29 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
CA2779681A1 (en) | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
CN101745352B (en) * | 2009-12-15 | 2012-05-30 | 中国科学院化学研究所 | Superhydrophobic surface material and special nano-particles thereof with core-shell structures |
CA2789229A1 (en) | 2010-02-10 | 2011-08-18 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
US20130303763A1 (en) | 2012-03-30 | 2013-11-14 | Michael D. Gershon | Methods and compositions for the treatment of necrotizing enterocolitis |
CN102885783B (en) * | 2012-09-26 | 2014-04-16 | 复旦大学附属金山医院 | Nanometer medicament microspheres |
WO2016178876A2 (en) | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
CN111971284A (en) | 2017-12-27 | 2020-11-20 | 埃默里大学 | Combination modes of nucleoside and/or nadph oxidase (nox) inhibitors as myellis-specific antiviral agents |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006025A (en) | 1975-06-06 | 1977-02-01 | Polaroid Corporation | Process for dispersing sensitizing dyes |
EP0233559A1 (en) | 1986-02-08 | 1987-08-26 | Ishihara Sangyo Kaisha, Ltd. | Readily absorbable pharmaceutical composition |
DE3722837A1 (en) | 1987-07-10 | 1989-01-19 | Ruetgerswerke Ag | Ophthalmological depot product |
US4855221A (en) | 1987-07-13 | 1989-08-08 | Eastman Kodak Company | Photographic elements having oxonol dyes |
US4973465A (en) | 1986-12-05 | 1990-11-27 | Ire-Celltarg S.A. | Microcrystals comprising an active substance having an affinity for phospholipids, and at least one phospholipid, process of preparation |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5118528A (en) | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5318767A (en) | 1991-01-25 | 1994-06-07 | Sterling Winthrop Inc. | X-ray contrast compositions useful in medical imaging |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5174930A (en) * | 1986-12-31 | 1992-12-29 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions |
US5300739A (en) | 1992-05-26 | 1994-04-05 | Otis Elevator Company | Cyclically varying an elevator car's assigned group in a system where each group has a separate lobby corridor |
JP4439590B2 (en) * | 1992-06-10 | 2010-03-24 | エラン ファーマ インターナショナル,リミティド | Surface modified NSAID nanoparticles |
GB9216082D0 (en) * | 1992-07-28 | 1992-09-09 | Univ Nottingham | Lymphatic delivery composition |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5260478A (en) | 1992-12-08 | 1993-11-09 | Sterling Winthrop Inc. | Iodinated aroyloxy carboxamides |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5322679A (en) | 1992-12-16 | 1994-06-21 | Sterling Winthrop Inc. | Iodinated aroyloxy esters |
US5264610A (en) | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
WO1995012386A1 (en) * | 1993-11-04 | 1995-05-11 | Schering Aktiengesellschaft | Charged liposome preparation |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
-
1996
- 1996-08-14 US US08/696,754 patent/US5834025A/en not_active Ceased
- 1996-09-25 WO PCT/US1996/015300 patent/WO1997011686A1/en active Application Filing
- 1996-09-25 EP EP10181619A patent/EP2275094A3/en not_active Withdrawn
- 1996-09-25 JP JP51356997A patent/JP2001518059A/en not_active Withdrawn
- 1996-09-25 AU AU71171/96A patent/AU7117196A/en not_active Abandoned
- 1996-09-25 CA CA002232879A patent/CA2232879C/en not_active Expired - Lifetime
- 1996-09-25 EP EP96932321A patent/EP0859604A4/en not_active Ceased
-
2008
- 2008-02-06 US US12/027,100 patent/USRE41884E1/en not_active Expired - Lifetime
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4006025A (en) | 1975-06-06 | 1977-02-01 | Polaroid Corporation | Process for dispersing sensitizing dyes |
EP0233559A1 (en) | 1986-02-08 | 1987-08-26 | Ishihara Sangyo Kaisha, Ltd. | Readily absorbable pharmaceutical composition |
US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
US4973465A (en) | 1986-12-05 | 1990-11-27 | Ire-Celltarg S.A. | Microcrystals comprising an active substance having an affinity for phospholipids, and at least one phospholipid, process of preparation |
US5118528A (en) | 1986-12-31 | 1992-06-02 | Centre National De La Recherche Scientifique | Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles |
DE3722837A1 (en) | 1987-07-10 | 1989-01-19 | Ruetgerswerke Ag | Ophthalmological depot product |
US4855221A (en) | 1987-07-13 | 1989-08-08 | Eastman Kodak Company | Photographic elements having oxonol dyes |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5318767A (en) | 1991-01-25 | 1994-06-07 | Sterling Winthrop Inc. | X-ray contrast compositions useful in medical imaging |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Non-Patent Citations (119)
Title |
---|
"Advertising Information for AZoNano.com for 2007," http://www.azonano.com/Advertising-pack.asp, 2007. |
"Digitalis," http://www.ch.ic.ac.uk/vchemlib/mim/bristol/digitalis/digitalis_text.htm. |
"Dynamic Light Scattering: An Introduction in 30 Minutes," Malvern Instruments Limited, DLS technical note MRK656-01. |
"Remington's Pharmaceutical Sciences," Mack Publishing Company, Easton, Pennsylvania, 1985, pp. 1585-1602. |
[Litigation document] Abraxis' 35 USC Section 282 Disclosure. |
[litigation document] Abraxis's Answering Claim Construction Brief; Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., Jun. 22, 2007. |
[Litigation document] Abraxis's Opening Brief in Support of Motion to Amend the Judgment and Enter Findings That Elan Engaged in Inequitable Conduct in Procuring the '363 and '025 Patents. |
[litigation document] Abraxis's Opening Claim Construction Brief (Redacted-Public Version); Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., May 11, 2007. |
[litigation document] Complaint and Exhibits Thereto; Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., Jul. 19, 2006. |
[Litigation document] Defendant Abraxis Bioscience, Inc.'s Opening Brief in Support of Its Motion to For Judgment As A Matter Of Law Of Noninfringement, Invalidity, inequitable Conduct, And Its Motion For New Trial. |
[litigation document] Docket Sheet in Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc. |
[Litigation document] Exhibit DX-020; U.S. Patent No. 4,826,689. |
[Litigation document] Exhibit DX-027; U.S. Patent No. 5,498,421. |
[Litigation document] Exhibit DX-028; U.S. Patent No. 6,096,331. |
[Litigation document] Exhibit DX-029; U.S. Patent No. 6,506,405 B1. |
[Litigation document] Exhibit DX-030; U.S. Patent No. 6,537,579 B1. |
[Litigation document] Exhibit DX-031; U.S. Patent No. 6,749,868 B1. |
[Litigation document] Exhibit DX-032; U.S. Patent No. 6,753,006 B1. |
[Litigation document] Exhibit DX-213; Liversidge et al., "Particle Size Reduction for Improvement of Oral Bioavailability of Hydrophobic Drugs: 1. Absolute Oral Bioavailability of NanoCrystalline Danazol in Beagle Dogs," International Journal of Pharmaceutics, vol. 125, pp. 91-97 (1995). |
[Litigation document] Exhibit DX-290; German Patent Application No. DE 37 22 837 A1. |
[Litigation document] Exhibit DX-354; J. Krantz et al., "XXVI. Pharmacodynamic Studies of Polyoxyalkylene Derivatives of Hexitol Anhydride Partial Fatty Acid Esters," Journal of Pharmacology and Experimental Therapeutics, vol. 93, pp. 188-195 (1948). |
[Litigation document] Exhibit DX-355; J. Krantz et al., "XXVII. Drug Allergy in the Canine Family," Journal of Pharmacology and Experimental Therapeutics, vol. 93, pp. 125-128 (1949). |
[Litigation document] Exhibit DX-356; A. Goth et al., "Effect of Corisone on Histamine Liberation Induced by Tween in the Dog," Proceedings of the Society for Experimental Biology and Medicine, vol. 78, pp. 848-852 (1951). |
[Litigation document] Exhibit DX-356; J.L. Schmidt et al., "Effect of Polyoxethylene Sorbitanmonostearate (Tween 60) on Circulation," Proceedings of the Society for Experimental Biology and Medicine, vol. 78, pp. 413 (1951). |
[Litigation document] Exhibit DX-357; J. Krantz et al., "Sugar Alcohols-XXVIII. Toxicologic, Pharmacodynamic and Clinical Observations on Tween 80*," Bulletin of the School of Medicine, University of Maryland, vol. 36, pp. 48-56 (1951). |
[Litigation document] Exhibit DX-358; W. Gough et al., "Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs," Journal of Cardiovascular Pharmacology, vol. 4, pp. 375-380 (1982). |
[Litigation document] Exhibit DX-359; A. Munoz et al., "A Randomized Hemodynamic Comparison of Intravenous Amiodarone With and Without Tween 80," European Heart Journal, vol. 9, pp. 142-148 (1988). |
[Litigation document] Exhibit DX-360; J. Ostensen et al., "Intravenous Injection of AlbunexR Microspheres Causes Thromboxane Mediated Pulmonary Hypertension in Pigs, But Not in Monkeys or Rabbits," Acta Physiologica Scandinavica, vol. 144, pp. 307-315 (1992). |
[Litigation document] Exhibit DX-361; E. Holtz et al., "Hemodynamic Responses to Particulate Contrast Media: Choice of Animal Species," Contrast Media Research (Jul. 8-12, 1991). |
[Litigation document] Exhibit DX-362; P.H. Elworthy et al., "Physiological Activity of Nonionic Surfactants," Chapter 28, Nonionic Surfactants, pp. 923-970 (1967). |
[Litigation document] Exhibit DX-407; H. Abdou, "Dissolution," Chapter 35, Remington's Pharmaceutical Sciences, pp. 653-666 (1995). |
[Litigation document] Exhibit DX-428; E. Macy et al., "Anaphylaxis to Infusion of Autologous Bone Marrow: An Apparent Reaction to Self, Mediated by IgE Antibody to Bovine Serum Albumin," The Journal of Allergy and Clinical Immunology, vol. 83, No. 5, pp. 871-875 (May 1989). |
[Litigation document] Exhibit DX-432; E.Y. Shami et al., "Stabilization of Enzymes by Their Specific Antibodies," Enzyme Microb, Technol., vol. 13, pp. 424-429 (May 1991). |
[Litigation document] Exhibit DX-434; S. Harvey et al., "Hormones," Chapter 50, Remington's Pharmaceutical Sciences, pp. 948, 968, 986-988, 990-993, 998, 1001 (1990). |
[Litigation document] Exhibit DX-434; S. Harvey, "Antimicrobial Drugs," Chapter 62, Remington's Pharmaceutical Sciences, pp. 1163, 1179, 1238-1240 (1990). |
[Litigation document] Exhibit DX-434; S. Harvey, "Antineoplastic and Immunoactive Drugs," Chapter 61, Remington's Pharmaceutical Sciences, pp. 1138-1162 (1990). |
[Litigation document] Exhibit DX-434; S. Harvey, "Topical Drugs," Chapter 38, Remington's Pharmaceutical Sciences, pp. 757, 768 (1990). |
[Litigation document] Exhibit DX-490; E. Ripple, "Powders," Chapter 89, Remington's Pharmaceutical Sciences, pp. 1585-1602 (1985). |
[Litigation document] Exhibit DX-491; R. Rowe et al., "Handbook of Pharmaceutical Excipients," Fourth Edition, pp. 11-12 (2003). |
[Litigation document] Exhibit DX-548; U.S. Patent No. 4,107,288. |
[Litigation document] Exhibit DX-549; U.S. Patent No. 4,540,602. |
[Litigation document] Exhibit DX-550; U.S. Patent No. 5,049,322. |
[Litigation document] Exhibit DX-552; U.S. Patent No. 5,439,686. |
[Litigation document] Exhibit DX-584; U.S. Patent No. 2,671,750. |
[Litigation document] Exhibit DX-585; U.S. Patent No. 3,881,020. |
[Litigation document] Exhibit DX-586; U.S. Patent No. 4,225,581. |
[Litigation document] Exhibit DX-587; U.S. Patent No. 4,269,821. |
[Litigation document] Exhibit DX-588; U.S. Patent No. 4,851,421. |
[Litigation document] Exhibit DX-590; U.S. Patent No. 5,124,338. |
[Litigation document] Exhibit DX-591; European Patent Application No. EP 0 262 560 A2. |
[Litigation document] Exhibit DX-592; European Patent Specification No. EP 0 411 629 B1. |
[Litigation document] Exhibit DX-593; European Patent Specification No. EP 0 499 299 B1. |
[Litigation document] Exhibit DX-594; French Patent No. FR 2 118 987. |
[Litigation document] Exhibit DX-596; Japanese Patent Abstract No. 02282330 A. |
[Litigation document] Exhibit DX-597; UK Patent Application No. 2 185 397 A. |
[Litigation document] Exhibit DX-598; UK Patent Application No. 2 200 048 A. |
[Litigation document] Exhibit DX-599; International Publication No. WO 84/00294. |
[Litigation document] Exhibit DX-600; International Publication No. WO 91/15193. |
[Litigation document] Exhibit DX-601; International Publication No. WO 90/15593. |
[Litigation document] Exhibit DX-602; International Publication No. WO 92/03380. |
[Litigation document] Exhibit DX-603; International Publication No. WO 91/06292. |
[Litigation document] Exhibit JX039; File History of U.S. Patent No. 5,399,363 (Liversidge et al.). |
[Litigation document] Judgment. |
[Litigation document] Jury Verdict. |
[litigation document] Order Construing the Terms of U.S. Patent Nos. 5,399,363 and 5,834,025; Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., Aug. 17, 2007. |
[litigation document] Plaintiff Élan Pharma International Limited's Answering Claim Construction Brief (Redacted: Public Version); Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., Jun. 22, 2007. |
[litigation document] Plaintiff Élan Pharma International Limited's Opening Claim Construction Brief; Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc., May 11, 2007. |
[litigation document] Wong 0000014-31; Fax dated Sep. 28, 2007, "Digitalis", Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc. |
[litigation document] Wong 0000042-60; Fax dated Sep. 28, 2007, Chapter 1-Introduction, http://www2.chemie.uni-erlangen.de/services/dissonline/data/dissertation/Christoph_Wabel/html/index.html, Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc. |
[litigation document] Wong 0000069-70; Fax dated Sep. 28, 2007, "References", Élan Pharmaceutical International Limited v. Abraxis Bioscience, Inc. |
Amendment filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991. |
Amendment filed in U.S. Appl. No. 07/908,125 on Jun. 27, 1994. |
Amendment filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993. |
Bertrand et al., "Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators," Circulation. Jan. 18, 2000;101(2):131-6. |
Borish et al., "Intravenous desensitization to beta-lactam antibiotics," J Allergy Clin Immunol. Sep. 1987; 80(3 Pt 1): 314-9. |
Budavari et al., "The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals" Eleventh Edition, 1989, pp. 262, 610, 1188, 1298, 1299, 1435, THER-16, THER-17. |
Cowens et al., "Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)," Cancer Res. Jun. 15, 1993;53(12):2796-802. |
de Garavilla, et al., "Controlling the Acute Hemodynamic Effects Associated With IV Administration of Particulate Drug Dispersions in Dogs," Drug Development Research 37:86-96 (1996). |
Faithfull et al., "Cardiorespiratory consequences of fluorocarbon reaction in dogs," Biomater Artif Cells Artif Organs. 1988;16(1-3):463-72. |
Fisher-Hoch et al., "Unexpected adverse reactions during a clinical trial in rural west Africa," Antiviral Res. Aug. 1992; 19(2):139-47. |
Gabizon, Alberto, et al., "Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethlene-glycol Coated Liposomes", Cancer Research 54 (1994): pp. 987-992. |
Gennaro et al., "Remington's Pharmaceutical Sciences," Eighteenth Edition, Mack Publishing Company, Easton, Pennsylvania, 1990, pp. 768, 948, 968, 986, 988, 990-993, 998, 1001, 1138-1163, 1238-1240. |
Gill et al., "Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin," Journal of Clinical Oncology, vol. 13, No. 4 (Apr. 1995): pp. 996-1003. |
Greenberger et al., "Emergency administration of radiocontrast media in high-risk patients," J Allergy Clin Immunol. Apr. 1986; 77(4):630-4. |
Greenberger et al., "The prevention of immediate generalized reactions to radiocontrast media in high-risk patients," J Allergy Clin Immunol. Apr. 1991; 87(4):867-72. |
Haskell, "Nanotechnology for Drug Delivery," Pfizer, Inc. |
Information Disclosure Statement filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991. |
Information Disclosure Statement filed in U.S. Appl. No. 07/908,125 on Nov. 12, 1992. |
Information Disclosure Statement filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993. |
Kattan et al., "Phase I Clinical Trial and pharmacokinetic Evaluation of Doxorubicin Carried by Polyisohexylcyanoacrylate Nanoparticles," Investigational New Drugs, 10:191-199, 1992. |
Katz et al., "Amphotericin B And Hypertension," The Pediatric Infectious Disease Journal, vol. 13, No. 9, Sep. 1994, pp. 839-840. |
Kirkwood et al., "Current Cancer Therapeutics," First Edition, Current Medicine, p. 78, 1994. |
Kleinerman et al., "Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma," Am J Clin Oncol. Apr. 1995; 18(2):93-9. |
Levine et al., "Cardiopulmonary toxicity after liposomal amphotericin B infusion," Ann Intern Med. Apr. 15, 1991;114(8):664-6. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Amended Joint Claim Chart, filed Jul. 26, 2007. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Joint Claim Chart, filed Apr. 20, 2007. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Order Construing the Terms of U.S. Patent Nos. 5,399,363 and 5,834,025, filed Aug. 17, 2007. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Order, filed Dec. 17, 2007. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Plaintiff Elan Pharma International Limited's Brief in Support of Motion for Clarification of Order Construing the Terms of U.S. Patent No. 5,834,025, filed Aug. 31, 2007. |
Litigation Document, Elan Pharma International Limited v. Abraxis Bioscience, Inc., Plaintiff Elan Pharma International Limited's Motion for Clarification of Order Construing the Terms of U.S. Patent No. 5,834,025, filed Aug. 31, 2007. |
Lorenz et al., "Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent," Agents Actions. Mar. 1977; 7(1):63-7. |
Misbah et al., "Adverse effects of intravenous immunoglobulin," Drug Saf. Oct. 1993; 9(4):254-62. |
O'Donovan et al., "Sensitivity to Penicillin: Anaphylaxis and Desensitisation," The Lancet, vol. CCLI, vol. 2, Sep. 28, 1946, pp. 444-446. |
Rowinsky et al., "Taxol: a novel investigational antimicrotubule agent," J Natl Cancer Inst. Aug. 1, 1990;82(15):1247-59. |
Rule 132 Declaration of Eugene Cooper filed in U.S. Appl. No. 07/647,105 on Nov. 18, 1991. |
Rule 132 Declaration of Gary S. Liversidge filed in U.S. Appl. No. 07/908,125 on Sep. 13, 1993. |
Schwartz et al., "A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma," Invest New Drugs. 1995;13(1):77-82. |
Shchipunov et al., "Phospholipids at the oil/water interface: adsorption and interfacial phenomena in an electric field," Adv Colloid Interface Sci. Mar. 1991; 35:31-138. |
Slack et al., "Acute Hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration," J Pharm Sci. Jun. 1981; 70(6):660-4. |
Sneader, "The discovery of aspirin: a reappraisal," BMJ Dec. 23-30, 2000;321(7276):1591-4. |
Sullivan, "Antigen-specific desensitization of patients allergic to penicillin," J Allergy Clin Immunol. Jun. 1982; 69(6):500-8. |
Uziely et al., "Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies," J Clin Oncol. Jul. 1995; 13(7):1777-85. |
Valero et al., "Adverse reactions to vancomycin prophylaxis in cardiac surgery," J Cardiothorac Vasc Anesth. Dec. 1991; 5(6):574-6. |
van Nieuwenhuyzen et al., "Effects of lecithins and proteins on the stability of emulsions," Fett/Lipid 100 (1998), Nr. 7, S. 282-291. |
Weiss et al., "Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512)," Cancer Res. Oct. 15, 1988;48(20):5878-82. |
Wendel et al., "Penicillin allergy and desensitization in serious infections during pregnancy," N Engl J Med. May 9, 1985;312(19):1229-32. |
Wikipedia, "rate of infusion", 2008. * |
Wong et al., "Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema," J Allergy Clin Immunol. May 2000; 105(5):997-1001. |
Wong et al., "Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol," J Allergy Clin Immunol. Aug. 1994; 94(2 Pt 1):189-94. |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
US20110124656A1 (en) * | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine |
US9918948B2 (en) | 2009-11-20 | 2018-03-20 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
US10722478B2 (en) | 2010-06-24 | 2020-07-28 | Tonix Pharma Holdings Limited | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US9474728B2 (en) | 2010-06-24 | 2016-10-25 | Tonix Pharma Holdings Limited | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
US9149464B2 (en) | 2012-11-12 | 2015-10-06 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9913827B2 (en) | 2012-11-12 | 2018-03-13 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9630926B2 (en) | 2012-11-12 | 2017-04-25 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9452988B2 (en) | 2012-11-12 | 2016-09-27 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US9150517B2 (en) | 2012-11-12 | 2015-10-06 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
US10117936B2 (en) | 2013-03-15 | 2018-11-06 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10322094B2 (en) | 2013-03-15 | 2019-06-18 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10736859B2 (en) | 2013-03-15 | 2020-08-11 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10864176B2 (en) | 2013-03-15 | 2020-12-15 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10864175B2 (en) | 2013-03-15 | 2020-12-15 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US9956188B2 (en) | 2013-03-15 | 2018-05-01 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US11737991B2 (en) | 2013-03-15 | 2023-08-29 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US11839594B2 (en) | 2013-03-15 | 2023-12-12 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US9636408B2 (en) | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
US10500165B2 (en) | 2014-07-03 | 2019-12-10 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Purified therapeutic nanoparticles and preparation methods thereof |
US10357465B2 (en) | 2014-09-18 | 2019-07-23 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
US11026898B2 (en) | 2014-09-18 | 2021-06-08 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
US11826321B2 (en) | 2017-12-11 | 2023-11-28 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
Also Published As
Publication number | Publication date |
---|---|
EP2275094A2 (en) | 2011-01-19 |
WO1997011686A1 (en) | 1997-04-03 |
US5834025A (en) | 1998-11-10 |
JP2001518059A (en) | 2001-10-09 |
EP2275094A3 (en) | 2012-08-29 |
EP0859604A4 (en) | 2006-01-18 |
CA2232879C (en) | 2004-03-02 |
EP0859604A1 (en) | 1998-08-26 |
CA2232879A1 (en) | 1997-04-03 |
AU7117196A (en) | 1997-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE41884E1 (en) | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | |
EP0810853B1 (en) | Aerosols containing nanoparticle dispersions | |
US5534270A (en) | Method of preparing stable drug nanoparticles | |
US5565188A (en) | Polyalkylene block copolymers as surface modifiers for nanoparticles | |
DE69231345T2 (en) | Surface modified drug nanoparticles | |
US5429824A (en) | Use of tyloxapole as a nanoparticle stabilizer and dispersant | |
US5622938A (en) | Sugar base surfactant for nanocrystals | |
US5510118A (en) | Process for preparing therapeutic compositions containing nanoparticles | |
US5718919A (en) | Nanoparticles containing the R(-)enantiomer of ibuprofen | |
EP1478342B1 (en) | Sterile filtered nanoparticule formulations of budesonide having tyloxapol as a surface stabilizer | |
JP2009102420A (en) | Use of peg-derivatized lipid as surface stabilizer for nanoparticulate composition | |
NZ248727A (en) | Nanoparticles with x-ray contrast agent with high molecular weight surfactant adsorbed on the surface |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., NEW YORK Free format text: PATENT SECURITY AGREEMENT (SECOND LIEN);ASSIGNORS:ALKERMES, INC.;ALKERMES PHARMA IRELAND LIMITED;ALKERMES CONTROLLED THERAPEUTICS INC.;REEL/FRAME:026994/0245 Effective date: 20110916 Owner name: MORGAN STANLEY SENIOR FUNDING, INC., NEW YORK Free format text: PATENT SECURITY AGREEMENT (FIRST LIEN);ASSIGNORS:ALKERMES, INC.;ALKERMES PHARMA IRELAND LIMITED;ALKERMES CONTROLLED THERAPEUTICS INC.;REEL/FRAME:026994/0186 Effective date: 20110916 |
|
AS | Assignment |
Owner name: ALKERMES PHARMA IRELAND LIMITED, IRELAND Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 Owner name: ALKERMES CONTROLLED THERAPEUTICS INC., MASSACHUSET Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 Owner name: ALKERMES, INC., MASSACHUSETTS Free format text: RELEASE BY SECURED PARTY (SECOND LIEN);ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:029116/0379 Effective date: 20120924 |
|
AS | Assignment |
Owner name: EDT PHARMA HOLDINGS LIMITED, IRELAND Free format text: ASSET TRANSFER AGREEMENT;ASSIGNOR:ELAN PHARMA INTERNATIONAL LIMITED;REEL/FRAME:032672/0001 Effective date: 20110802 Owner name: ALKERMES PHARMA IRELAND LIMITED, IRELAND Free format text: CHANGE OF NAME;ASSIGNOR:EDT PHARMA HOLDINGS LIMITED;REEL/FRAME:032661/0663 Effective date: 20110914 |
|
AS | Assignment |
Owner name: ALKERMES SCIENCE ONE LIMITED, IRELAND Free format text: PROPERTY TRANSFER AGREEMENT;ASSIGNOR:ALKERMES PHARMA IRELAND LIMITED;REEL/FRAME:033522/0048 Effective date: 20140508 |
|
AS | Assignment |
Owner name: DARAVITA LIMITED, IRELAND Free format text: CHANGE OF NAME;ASSIGNOR:ALKERMES SCIENCE ONE LIMITED;REEL/FRAME:035279/0701 Effective date: 20140812 |
|
AS | Assignment |
Owner name: ALKERMES PHARMA IRELAND LIMITED, IRELAND Free format text: BUSINESS TRANSFER AGREEMENT;ASSIGNOR:DARAVITA LIMITED;REEL/FRAME:035409/0831 Effective date: 20150410 Owner name: DV TECHNOLOGY LLC, DELAWARE Free format text: ASSET TRANSFER AND LICENSE AGREEMENT;ASSIGNOR:ALKERMES PHARMA IRELAND LIMITED;REEL/FRAME:035410/0001 Effective date: 20150410 |
|
AS | Assignment |
Owner name: ORBIMED ROYALTY OPPORTUNITIES II, LP, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:RECRO TECHNOLOGY LLC;REEL/FRAME:035403/0288 Effective date: 20150410 |
|
AS | Assignment |
Owner name: RECRO TECHNOLOGY LLC, PENNSYLVANIA Free format text: CHANGE OF NAME;ASSIGNOR:DV TECHNOLOGY LLC;REEL/FRAME:035446/0904 Effective date: 20150410 |
|
AS | Assignment |
Owner name: DARAVITA LIMITED (F/K/A ALKERMES SCIENCE ONE LIMIT Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:035505/0696 Effective date: 20150422 |
|
AS | Assignment |
Owner name: RECRO GAINESVILLE LLC (F/K/A RECRO TECHNOLOGY LLC) Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:ORBIMED ROYALTY OPPORTUNITIES II, LP;REEL/FRAME:044164/0008 Effective date: 20171117 |
|
AS | Assignment |
Owner name: RECRO PHARMA, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RECRO GAINESVILLE LLC;REEL/FRAME:051670/0524 Effective date: 20191121 Owner name: BAUDAX BIO, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RECRO PHARMA, INC.;REEL/FRAME:051671/0536 Effective date: 20191121 |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, DELAWARE Free format text: SECURITY INTEREST;ASSIGNORS:BAUDAX BIO N.A. LLC;BAUDAX BIO LIMITED;BAUDAX BIO, INC.;REEL/FRAME:052891/0590 Effective date: 20200529 |